Cited by 120Cancer Cells and MetastasisColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Colorectal cancer organoid-stroma biobank allows subtype-specific assessment of individualized therapy responses

Open access
Farin, Henner F., Mosa, Mohammed H., Ndreshkjana, Benardina, Grebbin, Britta M., Ritter, Birgit, Menche, Constantin, Kennel, Kilian B., Ziegler, Paul K. +23 more·2023·Cancer Discovery

Published version of a preprint

Abstract

In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy efficacy. Patient-derived tumor organoids (PDTO) show enormous potential for preclinical testing; however, cultured tumor cells lose important characteristics, including the consensus molecular subtypes (CMS). To better reflect the cellular heterogeneity, we established the colorectal cancer organoid–stroma biobank of matched PDTOs and cancer-associated fibroblasts (CAF) from 30 patients. Context-specific phenotyping showed that xenotransplantation or coculture with CAFs improves the transcriptomic fidelity and instructs subtype-specific stromal gene expression. Furthermore, functional profiling in coculture exposed CMS4-specific therapeutic resistance to gefitinib and SN-38 and prognostic expression signatures. Chemogenomic library screening identified patient- and therapy-dependent mechanisms of stromal resistance including MET as a common target. Our results demonstrate that colorectal cancer phenotypes are encrypted in the cancer epithelium in a plastic fashion that strongly depends on the context. Consequently, CAFs are essential for a faithful representation of molecular subtypes and therapy responses ex vivo. Significance: Systematic characterization of the organoid–stroma biobank provides a resource for context dependency in colorectal cancer. We demonstrate a colorectal cancer subtype memory of PDTOs that is independent of specific driver mutations. Our data underscore the importance of functional profiling in cocultures for improved preclinical testing and identification of stromal resistance mechanisms. This article is featured in Selected Articles from This Issue, p. 2109

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-0050

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Farin, H. F., Mosa, M. H., Ndreshkjana, B., Grebbin, B. M., Ritter, B., Menche, C., Kennel, K. B., Ziegler, P. K., Szabó, L., Bollrath, J., Rieder, D., Michels, B. E., Kress, A., Bozlar, M., Darvishi, T., Stier, S., Kur, I.-M., Bankov, K., Kesselring, R., Fichtner-Feigl, S., Brüne, B., Goetze, T. O., Al-Batran, S.-E., Brandts, C. H., Bechstein, W. O., Wild, P. J., Weigert, A., Müller, S., Knapp, S., Trajanoski, Z., & Greten, F. R.
Affiliations
  • Goethe University Frankfurt (DE)
  • Georg Speyer Haus (DE)
  • Innsbruck Medical University (AT)
  • University of Freiburg (DE)
  • 8Department of General and Visceral Surgery, University of Freiburg, Freiburg, Germany.
  • Institute of Clinical Cancer Research (DE)
  • 9Institute of Clinical Cancer Research IKF, Frankfurt am Main, Germany.
Corresponding author
  • Farin, Henner F.
  • Greten, Florian R.
Venue
Cancer Discovery
Published
2023-07-25
Volume
13
Issue
10
Pages
2192-2211
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4385230305
Cited by
120
References
69
Citations by year
2026: 39 · 2025: 44 · 2024: 31 · 2023: 6
FWCI
14.57
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • LOEWE Center Frankfurt Cancer Institute (III L 5 - 519/03/03.001 - (0015))
  • Deutsche Forschungsgemeinschaft (FOR2438 - FA1334/2-2)
  • HORIZON EUROPE European Research Council (Advanced Grant PLASTICAN-101021078)
  • Innovative Medicines Initiative 2 (EUbOPEN grant n&#x00B0, 875510)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, patient-derived tumor organoids, cancer-associated fibroblasts, consensus molecular subtypes, tumor microenvironment, gefitinib resistance, MET, xenotransplantation, co-culture, preclinical drug testing
MeSH terms
Cancer-Associated Fibroblasts, Humans, Organoids, Tumor Cells, Cultured, Colorectal Neoplasms, Biological Specimen Banks, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review